Name: Latest research reports of Concord Biotech Ltd. authored by HDFC Securities and published by - Trendlyne research reports.
Item: Concord Biotech Ltd.
Rating: 3
Author: HDFC Securities

Concord Biotech Ltd.

NSE: CONCORDBIO | BSE: 543960 | ISIN: INE338H01029 | Industry: Biotechnology
| Expensive Performer

1678.7000 -33.60 (-1.96%)

NSE Apr 22, 2025 15:31 PM

36.99% Fall from 52W High

Volume: 53,564

Concord Biotech Ltd.

03 Aug 2023

1678.70

-1.96%

IPO Note- Concord Biotech Limited

IPO Note: Concord Biotech Ltd.

HDFC Securities

Issue Snapshot: Issue Open: Aug 04 Aug 08, 2023 Price Band: Rs. 705 741 (Discount of Rs 70 for all eligible employees) *Issue Size: 20,925,652 eq sh (Entirely Offer for sale including Employee reservation of 10,000 eq sh) Reservation for: QIB upto 50% eq sh Non-Institutional atleast 15% eq sh ((including 1/3rd for applications between Rs.2 lakhs to Rs.10 lakhs)) Retail atleast 35% eq sh Face Value: Rs 1 Book value: Rs 123.31 (March 31, 2023) Bid size: - 20 equity shares and in multiples thereof 100% Book built Issue IPO Note- Concord Biotech Limited

Concord Biotech Ltd. has lost -22.30% in the last 3 Months